| 34.23 0.15 (0.44%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.16 | 1-year : | 50.42 |
| Resists | First : | 36.95 | Second : | 43.16 |
| Pivot price | 32.87  |
|||
| Supports | First : | 31.95 | Second : | 28.86 |
| MAs | MA(5) : | 34.78  |
MA(20) : | 32.51 |
| MA(100) : | 36.26 |
MA(250) : | 37.02 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 65.5 |
D(3) : | 70.2 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 56.04 | Low : | 21.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VERA ] has closed below upper band by 33.2%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.42 - 34.62 | 34.62 - 34.82 |
| Low: | 33.16 - 33.4 | 33.4 - 33.64 |
| Close: | 33.85 - 34.22 | 34.22 - 34.56 |
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Tue, 01 Sep 2026
Vera Therapeutics to Participate at Upcoming Investor Conferences - globenewswire.com
Tue, 18 Aug 2026
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - simplywall.st
Mon, 17 Aug 2026
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Fri, 14 Aug 2026
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Wed, 12 Aug 2026
Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 117.9 (%) |
| Shares Short | 15,280 (K) |
| Shares Short P.Month | 13,520 (K) |
| EPS | -5.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.8 % |
| Return on Equity (ttm) | -91.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -339 (M) |
| Levered Free Cash Flow | -213 (M) |
| PE Ratio | -5.84 |
| PEG Ratio | 0 |
| Price to Book value | 6.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|